Fig. 2From: The value of local consolidative therapy in Osimertinib-treated non-small cell lung cancer with oligo-residual diseaseProgression-free survival (PFS) curves of LCT group and non-LCT group. The median PFS of LCT group was not reached and 12.8 months for patients in non-LCT group. LCT: local consolidative therapyBack to article page